Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
TKI preserved lung function in patients with fibrosing interstitial disease
Key clinical point: In patients with progressive fibrosing interstitial lung disease, nintedanib slowed substantially the decline in lung function.
Major finding: Relative to placebo, the annual rate of decline in forced vital capacity was lower on nintedanib (–80.1 vs. –187.8 ml; P less than .001).
Data Source: Phase 3, multinational, double-blind trial.
Disclosures: Dr. Flaherty reports no potential conflicts of interest. The study was funded by Boehringer-Ingelheim, which produces nintedanib.
Citation:
Flaherty KR et al. N Engl J Med. 2019 Sep 29. doi: 10.1056/NEJMoa1908681.